AMIX revenueQ1 2027$0
AMIX revenue was $0 in fiscal Q1 2027 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2026 it was $0, compared with $0 in fiscal 2025.
Autonomix Medical Inc. (AMIX) financials
For the twelve months ended Jun 30, 2026, Autonomix Medical Inc. reported $0 of revenue and -$16.11M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$16.11M
- Cash
- $3.46M
- Market cap
- $3.3M
FY2023FY2026
FY2023FY2026
FY2023FY2026
AMIX revenue and earnings growth
AMIX net incomeQ1 2027-$2.73M
AMIX net income was -$2.73M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$3.34M a year earlier. For the full fiscal 2026 it was -$16.71M, compared with -$11.41M in fiscal 2025.
AMIX free cash flowQ4 2026-$2.90M
AMIX free cash flow was -$2.90M in fiscal Q4 2026 (ended Mar 31, 2026), compared with -$8.27M a year earlier. For the full fiscal 2026 it was -$12.29M, compared with -$8.27M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $7.14M | $4.72M | $2.23M | $745.0K |
| Selling, general and admin | $9.89M | $6.86M | $5.25M | $1.25M |
| Operating income | -$17.03M | -$11.59M | -$12.03M | -$1.99M |
| Interest expense | $0 | $176.0K | $79.0K | $0 |
| Pre-tax income | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| EPS, basic | -$2.32 | -$6.46 | -$14.82 | -$0.17 |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $7.00M | $9.14M | $8.61M | $865.0K |
| Current assets | $7.58M | $9.61M | $9.39M | $865.0K |
| Total assets | $7.60M | $9.81M | $9.41M | $865.0K |
| Current liabilities | $1.71M | $1.71M | $777.0K | $221.0K |
| Short-term debt | - | - | $0 | - |
| Long-term debt | - | $0 | $1.00M | $0 |
| Total debt | - | $0 | $1.00M | $0 |
| Total liabilities | $1.71M | $1.71M | $1.78M | $221.0K |
| Shareholders' equity | $5.89M | $8.10M | $7.63M | $644.0K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Operating cash flow | -$12.28M | -$8.26M | -$6.60M | -$1.85M |
| Capital expenditures | $10.0K | $14.0K | $19.0K | $0 |
| Free cash flow | -$12.29M | -$8.27M | -$6.62M | -$1.85M |
| Investing cash flow | -$10.0K | -$14.0K | -$19.0K | $0 |
| Financing cash flow | $10.16M | $8.80M | $14.41M | $675.0K |
| Stock-based compensation | $529.0K | $1.63M | $618.0K | $0 |
| Depreciation and amortization | $12.0K | $183.0K | $81.0K | $0 |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $1.51M | $1.46M | $1.72M | $2.37M | $1.59M | $1.55M | $1.04M | $1.17M | $954.0K | $698.0K | $687.0K | $471.0K |
| Selling, general and admin | $1.25M | $1.28M | $1.62M | $5.17M | $1.83M | $1.70M | $1.70M | $1.66M | $1.80M | $1.72M | $2.24M | $793.0K |
| Operating income | -$2.77M | -$2.74M | -$3.34M | -$7.53M | -$3.42M | -$3.25M | -$2.75M | -$2.84M | -$2.75M | -$2.42M | -$2.92M | -$5.82M |
| Interest expense | - | $0 | $0 | $0 | $0 | $46.0K | $45.0K | $43.0K | $41.0K | $46.0K | $33.0K | $0 |
| Pre-tax income | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | -$2.71M | -$2.81M | -$2.70M | -$5.41M | -$3.11M | -$6.04M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$11.41M | -$2.71M | -$2.81M | -$2.70M | -$15.43M | -$3.11M | -$6.04M |
| EPS, basic | -$5.02 | - | -$0.36 | -$1.38 | -$22.69 | - | -$1.46 | -$2.27 | -$2.20 | - | -$3.07 | -$8.78 |
| EPS, diluted | - | - | - | - | - | - | - | - | - | - | -$0.23 | - |
| Diluted shares | - | - | - | - | - | - | - | - | - | - | 13.8M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.46M | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | $11.82M | $5.16M | $6.75M | $8.61M | $1.22M | - |
| Current assets | $3.96M | $7.58M | $10.19M | $7.89M | $8.98M | $9.61M | $11.93M | $5.35M | $7.08M | $9.39M | $1.69M | - |
| Total assets | $3.98M | $7.60M | $10.21M | $7.93M | $9.00M | $9.81M | $11.95M | $5.37M | $7.09M | $9.41M | $1.81M | - |
| Current liabilities | $818.0K | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M | $1.26M | $763.0K | $777.0K | $973.0K | - |
| Short-term debt | - | - | - | - | - | - | $1.13M | - | - | $0 | - | - |
| Long-term debt | - | - | - | - | - | $0 | $0 | $1.09M | $1.04M | $1.00M | - | - |
| Total debt | - | - | - | - | - | $0 | $1.13M | $1.09M | $1.04M | $1.00M | $1.46M | - |
| Total liabilities | $818.0K | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M | $2.34M | $1.81M | $1.78M | $7.40M | - |
| Shareholders' equity | $3.16M | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | $9.71M | $3.03M | $5.29M | $7.63M | -$5.59M | -$2.92M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.54M | -$2.89M | -$2.97M | -$3.82M | -$2.60M | -$8.26M | -$2.30M | -$1.60M | -$1.85M | -$6.65M | -$2.56M | -$1.14M |
| Capital expenditures | - | $3.0K | $7.0K | $0 | $0 | $14.0K | $5.0K | $0 | $5.0K | $19.0K | $16.0K | $0 |
| Free cash flow | - | -$2.90M | -$2.98M | -$3.82M | -$2.60M | -$8.27M | -$2.31M | -$1.60M | -$1.86M | -$6.67M | -$2.57M | -$1.14M |
| Investing cash flow | - | -$3.0K | -$7.0K | $0 | $0 | -$14.0K | -$5.0K | $0 | -$5.0K | -$19.0K | -$16.0K | $0 |
| Financing cash flow | $0 | -$35.0K | $5.43M | $2.71M | $2.06M | $8.80M | $8.97M | $0 | $0 | $14.41M | $1.65M | $350.0K |
| Stock-based compensation | $2.0K | $1.0K | $2.0K | $138.0K | $388.0K | $1.63M | $418.0K | $445.0K | $360.0K | $618.0K | $212.0K | $151.0K |
| Depreciation and amortization | $3.0K | $3.0K | $4.0K | $2.0K | $3.0K | $183.0K | $47.0K | $45.0K | $43.0K | $81.0K | $35.0K | $0 |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.85 | 4.45 | 6.18 | 5.31 | 4.57 | 5.63 | 5.31 | 4.26 | 9.27 | 12.09 | 1.73 | - |
| Debt to equity | - | - | - | - | - | 0.00 | 0.12 | 0.36 | 0.20 | 0.13 | - | - |
Source: XBRL data Autonomix Medical Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AMIX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AMIX | $0 | - | -$16.11M | - | $3.3M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
AMIX FAQ
5 questionsWhat is AMIX revenue?
Autonomix Medical Inc. (AMIX) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2026 was $0.Is AMIX profitable?
No. Autonomix Medical Inc. reported a net loss of $16.11M for the twelve months ended Jun 30, 2026.How much cash and debt does AMIX have?
Autonomix Medical Inc. reported $3.46M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did AMIX last report financial results?
The latest statements here come from Autonomix Medical Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this AMIX financial data come from?
Quantisnow builds these statements from the structured XBRL data Autonomix Medical Inc. files with the SEC. It is provided for information only and is not investment advice.